Vaccines are biological entity used to activate acquired immunity to control or prevent particular disease or a group of disease. Immunization is carried out in infants as well as in adults. Vaccination against various bacterial and viral diseases is an integral part of infectious disease control world-wide.
The global market for Disease Control and Prevention Vaccine was estimated to be worth US$ 41900 million in 2023 and is forecast to a readjusted size of US$ 84190 million by 2030 with a CAGR of 10.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Disease Control and Prevention Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Disease Control and Prevention Vaccine by region & country, by Type, and by Application.
The Disease Control and Prevention Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Disease Control and Prevention Vaccine.
麻豆原创 Segmentation
By Company
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
Segment by Type:
Live-Attenuated
Inactivated
Recombinant Sub Unit and Toxoid
Segment by Application
Pediatric Vaccine
Adult Vaccine
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Disease Control and Prevention Vaccine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Disease Control and Prevention Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Disease Control and Prevention Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Disease Control and Prevention Vaccine Product Introduction
1.2 Global Disease Control and Prevention Vaccine 麻豆原创 Size Forecast
1.3 Disease Control and Prevention Vaccine 麻豆原创 Trends & Drivers
1.3.1 Disease Control and Prevention Vaccine Industry Trends
1.3.2 Disease Control and Prevention Vaccine 麻豆原创 Drivers & Opportunity
1.3.3 Disease Control and Prevention Vaccine 麻豆原创 Challenges
1.3.4 Disease Control and Prevention Vaccine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Disease Control and Prevention Vaccine Players Revenue Ranking (2023)
2.2 Global Disease Control and Prevention Vaccine Revenue by Company (2019-2024)
2.3 Key Companies Disease Control and Prevention Vaccine Manufacturing Base Distribution and Headquarters
2.4 Key Companies Disease Control and Prevention Vaccine Product Offered
2.5 Key Companies Time to Begin Mass Production of Disease Control and Prevention Vaccine
2.6 Disease Control and Prevention Vaccine 麻豆原创 Competitive Analysis
2.6.1 Disease Control and Prevention Vaccine 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Disease Control and Prevention Vaccine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Disease Control and Prevention Vaccine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Live-Attenuated
3.1.2 Inactivated
3.1.3 Recombinant Sub Unit and Toxoid
3.2 Global Disease Control and Prevention Vaccine Sales Value by Type
3.2.1 Global Disease Control and Prevention Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Disease Control and Prevention Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Disease Control and Prevention Vaccine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pediatric Vaccine
4.1.2 Adult Vaccine
4.2 Global Disease Control and Prevention Vaccine Sales Value by Application
4.2.1 Global Disease Control and Prevention Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Disease Control and Prevention Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Disease Control and Prevention Vaccine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Disease Control and Prevention Vaccine Sales Value by Region
5.1.1 Global Disease Control and Prevention Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Disease Control and Prevention Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Disease Control and Prevention Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Disease Control and Prevention Vaccine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Disease Control and Prevention Vaccine Sales Value, 2019-2030
5.2.2 North America Disease Control and Prevention Vaccine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Disease Control and Prevention Vaccine Sales Value, 2019-2030
5.3.2 Europe Disease Control and Prevention Vaccine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Disease Control and Prevention Vaccine Sales Value, 2019-2030
5.4.2 Asia Pacific Disease Control and Prevention Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Disease Control and Prevention Vaccine Sales Value, 2019-2030
5.5.2 South America Disease Control and Prevention Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Disease Control and Prevention Vaccine Sales Value, 2019-2030
5.6.2 Middle East & Africa Disease Control and Prevention Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Disease Control and Prevention Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Disease Control and Prevention Vaccine Sales Value
6.3 United States
6.3.1 United States Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.3.2 United States Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.4.2 Europe Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.5.2 China Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.6.2 Japan Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.7.2 South Korea Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Disease Control and Prevention Vaccine Sales Value, 2019-2030
6.9.2 India Disease Control and Prevention Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Disease Control and Prevention Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GSK
7.1.1 GSK Profile
7.1.2 GSK Main Business
7.1.3 GSK Disease Control and Prevention Vaccine Products, Services and Solutions
7.1.4 GSK Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.1.5 GSK Recent Developments
7.2 Merck & Co., Inc
7.2.1 Merck & Co., Inc Profile
7.2.2 Merck & Co., Inc Main Business
7.2.3 Merck & Co., Inc Disease Control and Prevention Vaccine Products, Services and Solutions
7.2.4 Merck & Co., Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.2.5 Merck & Co., Inc Recent Developments
7.3 Pfizer
7.3.1 Pfizer Profile
7.3.2 Pfizer Main Business
7.3.3 Pfizer Disease Control and Prevention Vaccine Products, Services and Solutions
7.3.4 Pfizer Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi Recent Developments
7.4 Sanofi
7.4.1 Sanofi Profile
7.4.2 Sanofi Main Business
7.4.3 Sanofi Disease Control and Prevention Vaccine Products, Services and Solutions
7.4.4 Sanofi Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi Recent Developments
7.5 AstraZeneca PLC
7.5.1 AstraZeneca PLC Profile
7.5.2 AstraZeneca PLC Main Business
7.5.3 AstraZeneca PLC Disease Control and Prevention Vaccine Products, Services and Solutions
7.5.4 AstraZeneca PLC Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.5.5 AstraZeneca PLC Recent Developments
7.6 Sinovac Biotech Ltd
7.6.1 Sinovac Biotech Ltd Profile
7.6.2 Sinovac Biotech Ltd Main Business
7.6.3 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
7.6.4 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.6.5 Sinovac Biotech Ltd Recent Developments
7.7 Astellas Pharma Inc
7.7.1 Astellas Pharma Inc Profile
7.7.2 Astellas Pharma Inc Main Business
7.7.3 Astellas Pharma Inc Disease Control and Prevention Vaccine Products, Services and Solutions
7.7.4 Astellas Pharma Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.7.5 Astellas Pharma Inc Recent Developments
7.8 Serum Institute of India Pvt. Ltd
7.8.1 Serum Institute of India Pvt. Ltd Profile
7.8.2 Serum Institute of India Pvt. Ltd Main Business
7.8.3 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
7.8.4 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.8.5 Serum Institute of India Pvt. Ltd Recent Developments
7.9 Daiichi Sankyo
7.9.1 Daiichi Sankyo Profile
7.9.2 Daiichi Sankyo Main Business
7.9.3 Daiichi Sankyo Disease Control and Prevention Vaccine Products, Services and Solutions
7.9.4 Daiichi Sankyo Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.9.5 Daiichi Sankyo Recent Developments
7.10 Abbott Laboratories
7.10.1 Abbott Laboratories Profile
7.10.2 Abbott Laboratories Main Business
7.10.3 Abbott Laboratories Disease Control and Prevention Vaccine Products, Services and Solutions
7.10.4 Abbott Laboratories Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.10.5 Abbott Laboratories Recent Developments
7.11 Bharat Biotech International
7.11.1 Bharat Biotech International Profile
7.11.2 Bharat Biotech International Main Business
7.11.3 Bharat Biotech International Disease Control and Prevention Vaccine Products, Services and Solutions
7.11.4 Bharat Biotech International Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.11.5 Bharat Biotech International Recent Developments
7.12 Bavarian Nordic A/S
7.12.1 Bavarian Nordic A/S Profile
7.12.2 Bavarian Nordic A/S Main Business
7.12.3 Bavarian Nordic A/S Disease Control and Prevention Vaccine Products, Services and Solutions
7.12.4 Bavarian Nordic A/S Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.12.5 Bavarian Nordic A/S Recent Developments
7.13 CSL Limited
7.13.1 CSL Limited Profile
7.13.2 CSL Limited Main Business
7.13.3 CSL Limited Disease Control and Prevention Vaccine Products, Services and Solutions
7.13.4 CSL Limited Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.13.5 CSL Limited Recent Developments
7.14 Emergent BioSolutions Inc
7.14.1 Emergent BioSolutions Inc Profile
7.14.2 Emergent BioSolutions Inc Main Business
7.14.3 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Products, Services and Solutions
7.14.4 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.14.5 Emergent BioSolutions Inc Recent Developments
7.15 Inovio Pharmaceuticals Inc
7.15.1 Inovio Pharmaceuticals Inc Profile
7.15.2 Inovio Pharmaceuticals Inc Main Business
7.15.3 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Products, Services and Solutions
7.15.4 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.15.5 Inovio Pharmaceuticals Inc Recent Developments
7.16 Johnson & Johnson
7.16.1 Johnson & Johnson Profile
7.16.2 Johnson & Johnson Main Business
7.16.3 Johnson & Johnson Disease Control and Prevention Vaccine Products, Services and Solutions
7.16.4 Johnson & Johnson Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.16.5 Johnson & Johnson Recent Developments
7.17 Mitsubishi Tanabe Pharma Corporation
7.17.1 Mitsubishi Tanabe Pharma Corporation Profile
7.17.2 Mitsubishi Tanabe Pharma Corporation Main Business
7.17.3 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Products, Services and Solutions
7.17.4 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.17.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
7.18 Novavax Inc
7.18.1 Novavax Inc Profile
7.18.2 Novavax Inc Main Business
7.18.3 Novavax Inc Disease Control and Prevention Vaccine Products, Services and Solutions
7.18.4 Novavax Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.18.5 Novavax Inc Recent Developments
7.19 Panacea Biotec Ltd
7.19.1 Panacea Biotec Ltd Profile
7.19.2 Panacea Biotec Ltd Main Business
7.19.3 Panacea Biotec Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
7.19.4 Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.19.5 Panacea Biotec Ltd Recent Developments
7.20 Takeda Pharmaceutical Company Limited
7.20.1 Takeda Pharmaceutical Company Limited Profile
7.20.2 Takeda Pharmaceutical Company Limited Main Business
7.20.3 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Products, Services and Solutions
7.20.4 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue (US$ Million) & (2019-2024)
7.20.5 Takeda Pharmaceutical Company Limited Recent Developments
8 Industry Chain Analysis
8.1 Disease Control and Prevention Vaccine Industrial Chain
8.2 Disease Control and Prevention Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Disease Control and Prevention Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Disease Control and Prevention Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
听
听
*If Applicable.